(Registrieren)

Abbott Launches Next-Generation StarClose(R) SE Vascular Closure System

Geschrieben am 16-05-2008

Abbott Park, Illinois (ots/PRNewswire) -

- New Device Designed to Provide Fast, Safe and Secure Vessel
Closure Following Catheterization Procedures

Abbott today announced the launch of the StarClose(R) SE Vascular
Closure System, a next-generation vessel closure device engineered to
enable fast, safe and secure closure of the femoral artery access
site following a catheterization procedure. StarClose SE is available
in the United States and Europe.

StarClose SE, which stands for "Safe and Extravascular," builds
upon the premium design of its predecessor, StarClose, with more
ergonomically-friendly design features. StarClose SE advancements
include:


-- Improved ease of use, with an intuitive, numbered system, providing
visual guidance and audible "clicks" for each step leading to clip
deployment
-- Immediate vessel closure with deployment of a shape-memory clip onto
the surface of an artery, allowing patients to recover and be
discharged sooner than with manual compression
-- Added device stability for the operator during clip deployment


"With a more ergonomic stabilizer and simpler, numbered-step
deployment, StarClose SE offers users the ability to close an artery
in a fast, safe and effective manner following a catheterization
procedure," said David Lee, M.D., assistant professor of Medicine and
director of Cardiac Catheterization and Coronary Intervention
Laboratories at the Stanford School of Medicine. "With its definitive
mechanical closure, StarClose SE enables an operator to confirm a
reliable closure immediately, which offers important benefits for
physicians and patients in reducing patient time to mobility
following these procedures."

StarClose SE utilizes the same nitinol (nickel and titanium) clip
technology as StarClose to close the femoral artery access site after
a catheterization procedure. When deployed, the small nitinol clip
grasps the tissue on top of the artery around the access site in a
purse-string fashion and closes the opening in the femoral artery
rapidly and securely with minimal affect to the lumen diameter or the
blood flow inside the vessel.

"We are pleased to introduce StarClose SE to advance the secure
closure of the vascular access site following catheterization
procedures," said Charles Simonton, M.D., FACC, FSCAI, divisional
vice president, Medical Affairs and chief medical officer, Abbott
Vascular. "StarClose SE was carefully designed to preserve the
safety, reliability and extravascular closure of our first-generation
technology, while providing enhanced ease of use for physicians."

For important safety information about StarClose SE, as well as
additional information about this product, please refer to Abbott's
Web site.

About Catheterization

Catheterization is a procedure commonly used to evaluate or treat
certain types of disease in vessels of the heart and other parts of
the body. The procedure involves the insertion of a flexible tube,
called a catheter, into the femoral artery in the leg. The physician
will use the catheter to observe the condition of the coronary or
peripheral blood vessels or to treat blockages in the vessels.
Following the procedure, the physician will remove the catheter and
close the femoral artery access site.

Over the years, a variety of methods, such as direct pressure
(manual compression), sandbags and mechanical clamps, have been used
to close the puncture site and achieve hemostasis (cessation of
bleeding). Many of these methods have proved less than satisfactory,
causing patients significant discomfort and requiring up to several
hours of bedrest.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's
leading vascular care businesses. Abbott Vascular is uniquely focused
on advancing the treatment of vascular disease and improving patient
care by combining the latest medical device innovations with
world-class pharmaceuticals, investing in research and development,
and advancing medicine through training and education. Headquartered
in Northern California, Abbott Vascular offers a comprehensive
portfolio of vessel closure, endovascular and coronary products that
are recognized internationally for their safety and effectiveness in
treating patients with vascular disease.

About Abbott

Abbott is a global, broad-based health care company devoted to
the discovery, development, manufacture and marketing of
pharmaceuticals and medical products, including nutritionals, devices
and diagnostics. The company employs more than 68,000 people and
markets its products in more than 130 countries.

Abbott's news releases and other information are available on the
company's Web site at http://www.abbott.com.

Web site: http://www.abbott.com

ots Originaltext: Abbott Laboratories
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Media, Karin Bauer, +1-650-868-2999, or Financial, Tina Ventura,
+1-847-935-9390, both of Abbott


Kontaktinformationen:

Leider liegen uns zu diesem Artikel keine separaten Kontaktinformationen gespeichert vor.
Am Ende der Pressemitteilung finden Sie meist die Kontaktdaten des Verfassers.

Neu! Bewerten Sie unsere Artikel in der rechten Navigationsleiste und finden
Sie außerdem den meist aufgerufenen Artikel in dieser Rubrik.

Sie suche nach weiteren Pressenachrichten?
Mehr zu diesem Thema finden Sie auf folgender Übersichtsseite. Desweiteren finden Sie dort auch Nachrichten aus anderen Genres.

http://www.bankkaufmann.com/topics.html

Weitere Informationen erhalten Sie per E-Mail unter der Adresse: info@bankkaufmann.com.

@-symbol Internet Media UG (haftungsbeschränkt)
Schulstr. 18
D-91245 Simmelsdorf

E-Mail: media(at)at-symbol.de

137161

weitere Artikel:
  • Hilco Consumer Capital, L.P. und GB Brands, LLC bekommen "Stalking Horse"-Gebot für The Sharper Image zugesprochen Toronto, Kanada (ots/PRNewswire) - Ein von Hilco Consumer Capital, L.P. ("HCC") und GB Brands, LLC ("GBB") in Partnerschaft mit Windsong Brands, LLC und Crystal Capital geführtes Joint Venture gab heute bekannt, dass es die Erlaubnis erhalten hat, als "Stalking Horse"-Bieter für gewisse Anteile des Vermögens der The Sharper Image Corporation zu fungieren. HCC und GBB haben eine weltweite Lizenzvergabestrategie für Gross- und Einzelhandel, DTR (Direct-to-retail), E-Commerce und Kataloggeschäfte entwickelt, die die Hinterlassenschaft aus Qualität, mehr...

  • Eurocastle Announces the Refinancing of Two Debt Facilities Guernsey (ots) - Eurocastle Investment Limited (Frankfurt Stock Exchange: EUI1 and Euronext Amsterdam: ECT) today announced that it has signed the refinancing of approximately EUR 330 million (representing all of the outstanding short term tranche due July 2008) of the original EUR 1.6 billion credit facility put in place in respect of the MARS portfolio. The new facility, which is non- recourse to Eurocastle, becomes effective upon the satisfaction of customary conditions precedent and will amortize down to EUR 200 million mehr...

  • "Campus Derendorf" kommt - Bau und Liegenschaftsbetrieb NRW realisiert Fachhochschule im Düsseldorfer Norden Düsseldorf (ots) - Der Bau- und Liegenschaftsbetrieb NRW plant in Düsseldorf-Derendorf auf dem ehemaligen Schlösser-Gelände und dem angrenzenden Schlachthof-Areal den Neubau der Fachhochschule Düsseldorf. "Der erste Bauabschnitt soll bereits 2012 fertig gestellt werden", erklärt Ferdinand Tiggemann, Geschäftsführer des Bau- und Liegenschaftsbetriebes NRW. Mit der Entscheidung für einen Hochschulstandort im Düsseldorfer Norden wird die Fachhochschule in ihrer weiteren Entwicklung gestärkt. Die Fachhochschule Düsseldorf ist mit einem mehr...

  • 2,8% mehr Beschäftigte im Verarbeitenden Gewerbe im März 2008 Wiesbaden (ots) - Ende März 2008 waren in den Betrieben des Verarbeitenden Gewerbes mit 50 und mehr Beschäftigten gut 5,3 Millionen Personen tätig. Wie das Statistische Bundesamt (Destatis) weiter mitteilt, waren dies rund 147 500 Personen oder 2,8% mehr als im März 2007. Die Zahl der im März 2008 geleisteten Arbeitsstunden nahm im Vergleich zum entsprechenden Vorjahresmonat um 7,2% auf 675 Millionen ab. Dabei ist zu berück-sichtigen, dass es im Berichtsmonat 19 Arbeitstage gab und somit drei weniger als im März 2007. Die Entgelte mehr...

  • Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients With Advanced Breast Cancer London (ots/PRNewswire) - - Phase II Data Presented at ASCO Showed Acceptable Tolerability Profile, with Low Incidence of Grade 3 and 4 Neuropathy Eisai Europe Ltd. The investigational chemotherapeutic agent eribulin mesylate (E7389) demonstrated activity in a heavily pretreated population of women with locally advanced or metastatic breast cancer, according to results of a multi-center Phase II clinical trial. The study also suggests that eribulin mesylate has a manageable tolerability profile, with a low incidence of Grade 3 (severe) mehr...

Mehr zu dem Thema Aktuelle Wirtschaftsnews

Der meistgelesene Artikel zu dem Thema:

DBV löst Berechtigungsscheine von knapp 344 Mio. EUR ein

durchschnittliche Punktzahl: 0
Stimmen: 0

Bitte nehmen Sie sich einen Augenblick Zeit, diesen Artikel zu bewerten:

Exzellent
Sehr gut
gut
normal
schlecht